gabapentin has been researched along with Squamous Cell Carcinoma of Head and Neck in 3 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Squamous Cell Carcinoma of Head and Neck: The most common type of head and neck carcinoma that originates from cells on the surface of the NASAL CAVITY; MOUTH; PARANASAL SINUSES, SALIVARY GLANDS, and LARYNX. Mutations in TNFRSF10B, PTEN, and ING1 genes are associated with this cancer.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this paper is to determine whether prophylactic gabapentin usage in patients undergoing definitive concurrent chemotherapy and radiation therapy (chemoRT) for oropharyngeal cancer (OPC) improves treatment-related oral mucositis pain, opioid use, and feeding tube (FT) placement." | 9.51 | Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. ( Ali, H; Chang, S; Cook, A; Fakhoury, L; Ghanem, T; Han, X; Modh, A; Momin, S; Money, S; Movsas, B; Sheqwara, J; Siddiqui, F; Tam, S; Wu, V, 2022) |
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 9.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "The purpose of this paper is to determine whether prophylactic gabapentin usage in patients undergoing definitive concurrent chemotherapy and radiation therapy (chemoRT) for oropharyngeal cancer (OPC) improves treatment-related oral mucositis pain, opioid use, and feeding tube (FT) placement." | 5.51 | Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. ( Ali, H; Chang, S; Cook, A; Fakhoury, L; Ghanem, T; Han, X; Modh, A; Momin, S; Money, S; Movsas, B; Sheqwara, J; Siddiqui, F; Tam, S; Wu, V, 2022) |
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 5.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "Pain was not found to be different between the treatment arms." | 2.94 | A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer. ( Attwood, K; Bourgeois, DJ; Hermann, GM; Iovoli, AJ; Miller, A; Platek, AJ; Singh, AK; Wang, C, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cook, A | 1 |
| Modh, A | 1 |
| Ali, H | 1 |
| Sheqwara, J | 1 |
| Chang, S | 1 |
| Ghanem, T | 1 |
| Momin, S | 1 |
| Wu, V | 1 |
| Tam, S | 1 |
| Money, S | 1 |
| Han, X | 1 |
| Fakhoury, L | 1 |
| Movsas, B | 1 |
| Siddiqui, F | 1 |
| Hermann, GM | 1 |
| Iovoli, AJ | 1 |
| Platek, AJ | 1 |
| Wang, C | 1 |
| Miller, A | 1 |
| Attwood, K | 1 |
| Bourgeois, DJ | 1 |
| Singh, AK | 1 |
| Kataoka, T | 1 |
| Kiyota, N | 1 |
| Shimada, T | 1 |
| Funakoshi, Y | 1 |
| Chayahara, N | 1 |
| Toyoda, M | 1 |
| Fujiwara, Y | 1 |
| Nibu, K | 1 |
| Komori, T | 1 |
| Sasaki, R | 1 |
| Mukohara, T | 1 |
| Minami, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma[NCT03269344] | Phase 3 | 65 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03269344)
Timeframe: Over the entire study period from baseline to follow-up, approximately 13 weeks
| Intervention | Daily morphine equivalents (Median) |
|---|---|
| Control Arm | 15.6 |
| Experimental Arm | 22.2 |
Scale: Patient-reported outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE), 5-point Likert scale, higher scores indicate worse outcomes. Range of scores 0-40 (min-max). (NCT03269344)
Timeframe: Evaluated change in scores from baseline to 6 weeks post-treatment, approximately 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Control Arm | 1.0 |
| Experimental Arm | 6.5 |
Scale tile: Patient Reported Oral Mucositis Symptoms scale, range 0-1000, higher scores indicate worse outcomes (NCT03269344)
Timeframe: Evaluated change in scores from baseline to 6 weeks post-treatment, approximately 13 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Control Arm | 20.1 |
| Experimental Arm | 29.1 |
Scale: Functional Assessment of Cancer Therapy-Trial Outcome (FACT-HN), range 0-148, higher scores indicate better outcomes (NCT03269344)
Timeframe: Administered at baseline and at 6-week follow-up endpoint, approximately 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Control Arm | -15.0 |
| Experimental Arm | -20.0 |
Measure of number of patients who required feeding tube placement at any time during the study period (NCT03269344)
Timeframe: Evaluated placement of feeding tube from baseline (start of radiation) to 6 weeks post-treatment, approximately 13 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Arm | 6 |
| Experimental Arm | 18 |
Percent weight lost from baseline to week 7 of treatment (end of treatment) (NCT03269344)
Timeframe: Percent change from baseline to week 7 of treatment
| Intervention | Percent change (Median) |
|---|---|
| Control Arm | -10.7 |
| Experimental Arm | -11.4 |
3 trials available for gabapentin and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma.
Topics: Double-Blind Method; Gabapentin; Head and Neck Neoplasms; Humans; Pain; Quality of Life; Squamous Ce | 2022 |
A single-institution, randomized, pilot study evaluating the efficacy of gabapentin and methadone for patients undergoing chemoradiation for head and neck squamous cell cancer.
Topics: Adult; Aged; Analgesics; Chemoradiotherapy; Dose-Response Relationship, Drug; Female; Gabapentin; Hu | 2020 |
Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.
Topics: Acetaminophen; Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Carcinoma | 2016 |